Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era

Carminia M. Della Corte; Carl M. Gay; Lauren A. Byers

doi:10.1002/cncr.31863

Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era

Carminia M. Della Corte, Carl M. Gay, Lauren A. Byers

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	496-498
Number of pages	3
Journal	Cancer
Volume	125
Issue number	4
DOIs	https://doi.org/10.1002/cncr.31863
State	Published - Feb 15 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.31863

Cite this

@article{f1b13f5c5bca4f68a9884d90db921075,

title = "Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era",

author = "{Della Corte}, {Carminia M.} and Gay, {Carl M.} and Byers, {Lauren A.}",

note = "Funding Information: Lauren A. Byers reports grants from Tolero; grants and personal fees from AstraZeneca, AbbVie, and GenMab; and personal fees from Bristol-Myers Squibb, PharmaMar, and Alethia Biotherapeutics Inc outside the submitted work. Carminia M. Della Corte and Carl M. Gay made no disclosures. Funding Information: This work was supported by grants from the National Institutes of Health/National Cancer Institute (R01-CA207295, U01-CA213273, P5-CA070907, and P30-CA01667 to Lauren A. Byers; T32-CA009666 to Carl M. Gay) and through generous philanthropic contributions to the University of Texas MD Anderson Lung Cancer Moon Shots Program (Lauren A. Byers).",

year = "2019",

month = feb,

day = "15",

doi = "10.1002/cncr.31863",

language = "English (US)",

volume = "125",

pages = "496--498",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Beyond chemotherapy

T2 - Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era

AU - Della Corte, Carminia M.

AU - Gay, Carl M.

AU - Byers, Lauren A.

N1 - Funding Information: Lauren A. Byers reports grants from Tolero; grants and personal fees from AstraZeneca, AbbVie, and GenMab; and personal fees from Bristol-Myers Squibb, PharmaMar, and Alethia Biotherapeutics Inc outside the submitted work. Carminia M. Della Corte and Carl M. Gay made no disclosures. Funding Information: This work was supported by grants from the National Institutes of Health/National Cancer Institute (R01-CA207295, U01-CA213273, P5-CA070907, and P30-CA01667 to Lauren A. Byers; T32-CA009666 to Carl M. Gay) and through generous philanthropic contributions to the University of Texas MD Anderson Lung Cancer Moon Shots Program (Lauren A. Byers).

PY - 2019/2/15

Y1 - 2019/2/15

UR - http://www.scopus.com/inward/record.url?scp=85059692456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059692456&partnerID=8YFLogxK

U2 - 10.1002/cncr.31863

DO - 10.1002/cncr.31863

M3 - Article

C2 - 30620399

AN - SCOPUS:85059692456

SN - 0008-543X

VL - 125

SP - 496

EP - 498

JO - Cancer

JF - Cancer

IS - 4

ER -

Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this